Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Progesterone Receptor Is Responsible for Benign Biology of Skull Base Meningioma.

Kuroi Y, Matsumoto K, Shibuya M, Kasuya H.

World Neurosurg. 2018 Oct;118:e918-e924. doi: 10.1016/j.wneu.2018.07.100. Epub 2018 Jul 19.

PMID:
30031954
2.

Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas.

Mansouri A, Klironomos G, Taslimi S, Kilian A, Gentili F, Khan OH, Aldape K, Zadeh G.

J Neurosurg. 2016 Aug;125(2):431-40. doi: 10.3171/2015.7.JNS15546. Epub 2016 Jan 1.

PMID:
26722844
3.

Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.

Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, van Trotsenburg M, Hainfellner JA, Knosp E.

Neurosurg Rev. 2004 Oct;27(4):238-45. Epub 2004 May 27.

PMID:
15168138
4.

Differential Tumor Progression Patterns in Skull Base Versus Non-Skull Base Meningiomas: A Critical Analysis from a Long-Term Follow-Up Study and Review of Literature.

Savardekar AR, Patra DP, Bir S, Thakur JD, Mohammed N, Bollam P, Georgescu MM, Nanda A.

World Neurosurg. 2018 Apr;112:e74-e83. doi: 10.1016/j.wneu.2017.12.035. Epub 2017 Dec 16. Review.

PMID:
29258946
5.

A comparison of clinicopathological features and surgical outcomes between pediatric skull base and non-skull base meningiomas.

Li Z, Li H, Jiao Y, Ma J, Wang S, Zhao J, Cao Y.

Childs Nerv Syst. 2017 Apr;33(4):595-600. doi: 10.1007/s00381-016-3278-9. Epub 2016 Oct 29.

PMID:
27796552
6.

Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.

Yesilöz Ü, Kirches E, Hartmann C, Scholz J, Kropf S, Sahm F, Nakamura M, Mawrin C.

Neuro Oncol. 2017 Aug 1;19(8):1088-1096. doi: 10.1093/neuonc/nox018.

7.

Inverse correlation of cell proliferation and expression of progesterone receptors in tumor spheroids and monolayer cultures of human meningiomas.

Tonn JC, Ott MM, Bouterfa H, Kerkau S, Kapp M, Müller-Hermelink HK, Roosen K.

Neurosurgery. 1997 Nov;41(5):1152-9.

PMID:
9361071
8.

A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.

McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY.

J Neurosurg. 2010 May;112(5):925-33. doi: 10.3171/2009.9.JNS09617.

PMID:
19799498
9.

Surgery of Small Anterior Skull Base Meningiomas by Endoscopic 5-Aminolevulinic Acid Fluorescence Guidance: First Clinical Experience.

Cornelius JF, Kamp MA, Tortora A, Knipps J, Krause-Molle Z, Beez T, Petridis AK, Sabel M, Schipper J, Steiger HJ.

World Neurosurg. 2019 Feb;122:e890-e895. doi: 10.1016/j.wneu.2018.10.171. Epub 2018 Nov 10.

PMID:
30419399
10.

Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse.

Tao Y, Liang G, Li Z, Wang Y, Wu A, Wang H, Lu Y, Liu Z, Hu G.

Br J Neurosurg. 2012 Oct;26(5):700-4. doi: 10.3109/02688697.2012.685780. Epub 2012 May 22.

PMID:
22616825
11.

Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases.

Cornelius JF, Slotty PJ, Steiger HJ, Hänggi D, Polivka M, George B.

Acta Neurochir (Wien). 2013 Mar;155(3):407-13. doi: 10.1007/s00701-012-1611-y. Epub 2013 Jan 15. Review.

PMID:
23318687
12.

Meningiomas Display a Specific Immunoexpression Pattern in a Rostrocaudal Gradient: An Analysis of 366 Patients.

Ülgen E, Bektaşoğlu PK, Sav MA, Can Ö, Danyeli AE, Hızal DB, Pamir MN, Özduman K.

World Neurosurg. 2019 Mar;123:e520-e535. doi: 10.1016/j.wneu.2018.11.201. Epub 2018 Nov 29.

PMID:
30503291
13.

Endoscopic Endonasal Craniofacial Surgery for Recurrent Skull Base Meningiomas Involving the Pterygopalatine Fossa, the Infratemporal Fossa, the Orbit, and the Paranasal Sinus.

Shin M, Shojima M, Kondo K, Hasegawa H, Hanakita S, Ito A, Kin T, Saito N.

World Neurosurg. 2018 Apr;112:e302-e312. doi: 10.1016/j.wneu.2018.01.041. Epub 2018 Jan 12.

PMID:
29339322
14.

The role of radical microsurgical resection in multimodal treatment for skull base meningioma.

Ichinose T, Goto T, Ishibashi K, Takami T, Ohata K.

J Neurosurg. 2010 Nov;113(5):1072-8. doi: 10.3171/2010.2.JNS091118. Epub 2010 Mar 12. Erratum in: J Neurosurg. 2010 Nov;113(5):1123.

PMID:
20225926
15.

Analysis of factors affecting the long-term functional outcome of patients with skull base meningioma.

Nakao N, Ohkawa T, Miki J, Nishibayahsi H, Ogura M, Uematsu Y, Itakura T.

J Clin Neurosci. 2011 Jul;18(7):895-8. doi: 10.1016/j.jocn.2010.10.020. Epub 2011 May 11.

PMID:
21565513
16.

[Skull base meningiomas: a predictive system to know the extent of their surgical resection and patient outcome].

Morales F, Maillo A, Díaz-Alvarez A, Merino M, Muñoz-Herrera A, Hernández J, Santamarta D.

Neurocirugia (Astur). 2005 Dec;16(6):477-85. Spanish.

17.

Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression.

Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H.

J Neurooncol. 2006 Oct;80(1):1-7. Epub 2006 May 13.

PMID:
16703453
18.

Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas.

Fakhrjou A, Meshkini A, Shadrvan S.

Pak J Biol Sci. 2012 Jun 1;15(11):530-5.

PMID:
24191627
19.

Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.

Kim M, Lee DH, Kim Rn HJ, Cho YH, Kim JH, Kwon DH.

Clin Neurol Neurosurg. 2017 Feb;153:93-101. doi: 10.1016/j.clineuro.2016.12.014. Epub 2016 Dec 29.

PMID:
28081463
20.

Clinical features and treatment of World Health Organization grade II and III meningiomas in childhood: report of 23 cases.

Wang XQ, Jiang CC, Zhao L, Gong Y, Hu J, Chen H.

J Neurosurg Pediatr. 2012 Nov;10(5):423-33. doi: 10.3171/2012.7.PEDS12179. Epub 2012 Aug 31. Erratum in: J Neurosurg Pediatr. 2012 Nov;10(5):459.

PMID:
22938082

Supplemental Content

Support Center